|
|
Study on General Properties of PEGylated Recombinant Uricase |
ZHAO Xing-xiu1,HE Yi-guo1,YAO Xing-chuan2,DU Lin-fang2,MENG Yan-fa2 |
1.Sichuan University of Science & Engineering,Zigong 643000,China
2.College of Life Science, Sichuan University,Chengdu 610064, China |
|
|
Abstract Induced by lactose, the recombinant Candida utilis uricase was expressed in the E.coli JM109(DE3) that carried the PET-uricase expression plasmid. The crude extraction was processed by the following purification procedures including ammonium sulfate precipitation, anion-exchange chromatography and gel filtration chromatography and the recombinant uricase with 95% purity could be obtained. Using HPLC and reduced SDS-PAGE, the native molecular weight of this enzyme and the apparent molecular weight of its subunit were determinied as 130 kDa and 33 kDa. The (mPEG)2-Lys-NHS of 20 kDa was used to modify the purified uricase and the study on zymological properties of uricase before and after modification was carried on. The results showed that the optimum pH of PEG modified uricase and native uricase were pH 7.5 and pH 8.5 respectively and both of them had good pHstability from pH 6 to 10; both of the two had the same optimum temperature of 40℃, but the thermal stability and the ability of antitrypsin hydrolysis of the pegylated enzyme were much better than those of native enzyme; the modified uricase retained 87.5% of the enzymatic activity of native uricase; under each optimum condition, the determined Km of uricase before and after pegylation were 3.91×10-5 mol/L and 3.57×10-5 mol/L respectively. These findings may provide some information for deep investigation of structure and function of pegylated uricase.
|
Received: 20 March 2009
Published: 07 December 2009
|
|
|
|
[1] |
Oda M, Satta Y, Takenaka O, et al. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol, 2002, 19(5): 640~653
|
|
|
[2] |
Baeksgaard L, Sorensen J B. Acute tumor lysis syndrome in solid tumorsa case report and review of the literature. Cancer Chemother Pharmacol, 2003, 51(3): 187~192
|
|
|
[3] |
Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine, 2004, 71(6): 481~485
|
|
|
[4] |
Nuki G. Treatment of crystal arthropathyhistory and advances. Rheum Dis Clin North Am, 2006, 32(2): 333~357
|
|
|
[5] |
才蕾, 高向东, 朱姝, 等. 聚乙二醇修饰尿酸酶的研究. 中国药科大学学报, 2008, 39(6): 557~562 Cai L, Gao X D, Zhu S, et al. Journal of China Pharmaceutical University, 2008, 39(6): 557~562
|
|
|
[6] |
Toyobo co. lid. Toyobo enzymes. Japan: Biochemical operations department, 1996.171
|
|
|
[7] |
汪家政, 范明. 蛋白质技术手册. 北京: 科学出版社, 2002.38~50 Wang J Z, Fan M.Protein Technical Manual. Beijing: Science Press, 2002.38~50
|
|
|
[8] |
Bomalaski J S, Holtsberg F W, Ensor C M, et al. Uricase formulated with polyethylene glycol (uricasePEG 20): biochemical rationale and preclinical studies. J Rheumatol, 2002, 29(9): 1942~1949
|
|
|
[9] |
Liao F, Zhu X Y, Wang Y M, et al. The comparison of the estimation of enzyme kinetic parameters by fitting reaction curve to the integrated MichaelisMenten rate equations of different predictor variables. J Biochem Biophys Methods, 2005, 62(1): 13~24
|
|
|
[10] |
Davis S, Park Y K, Abuchowski A, et al. Hypouricaemic effect of polyethyleneglycol modified urate oxidase. Lancet, 1981, 2(8241): 281~283
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|